Several MTDLs have progressed to clinical trials for treating AD, such as tramiprosate, which targets Aβ oligomers and Tau-protein aggregation simultaneously, ladostigil, a dual inhibitor against cholinesterase and monoamine oxidase, and blarcamesine, which functions as a sigma-1 receptor agonist and muscarinic receptor modulator [10]. This evidence concerns the gene MAPT and Alzheimer disease.